Table 4.

Summary of study A results—homologous vs heterologous protection to a PCV2a vaccine

Protection Endpoint	Treatment Group (T)
	T01—PCV2a challenge control	T02—cPCV2a Vaccine	T03—PCV2b challenge control*	T04—cPCV2a Vaccine*
	PCV2a challenge (homologous)		PCV2b challenge (heterologous)
	Ever positive positive #/total # (%)
Viremia	9/10 (90%)	5/10 (50%)	9/9 (100%)	7/10 (70%)
Fecal Shedding	9/10 (90%)	3/10 (30%)	9/9 (100%)	3/9 (33.3%)
Lymphoid Depletion (LD)	6/10 (60%)	0/10 (0%)	6/9 (66.7%)	4/9 (44.4%)
Histiocytic Replacement (HR)	2/10 (20%)	0/10 (0%)	6/9 (66.7%)	2/9 (22.2%)
Lymphoid Colonization (IHC)	7/10 (70%)	4/10 (40%)	7/9 (77.8%)	3/9 (33.3%)

^* One animal from T03 and one animal from T04 were removed for health reasons.